APA (7th ed.) Citation

YH, B., D, K., S, L., S, K., I, J., E, P., . . . SR, P. (2026). Neoadjuvant Danburstotug (IMC-001) therapy in gastric, esophageal, and hepatocellular carcinoma: The NeoChance phase II study. NPJ precision oncology. https://doi.org/10.1038/s41698-026-01571-2

Chicago Style (17th ed.) Citation

YH, Bang, et al. "Neoadjuvant Danburstotug (IMC-001) Therapy in Gastric, Esophageal, and Hepatocellular Carcinoma: The NeoChance Phase II Study." NPJ Precision Oncology 2026. https://doi.org/10.1038/s41698-026-01571-2.

MLA (9th ed.) Citation

YH, Bang, et al. "Neoadjuvant Danburstotug (IMC-001) Therapy in Gastric, Esophageal, and Hepatocellular Carcinoma: The NeoChance Phase II Study." NPJ Precision Oncology, 2026, https://doi.org/10.1038/s41698-026-01571-2.